New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 7, 2013
07:32 EDTHZNPHorizon Pharma gets U.K. marketing authorization for DUEXIS
Horizon Pharma announced that the United Kingdom Medicines and Healthcare products Regulatory Agency has granted marketing authorization for DUEXIS for the symptomatic treatment of osteoarthritis, rheumatoid arthritis and ankylosing spondylitis in patients who require regular treatment with high dose ibuprofen administered three times a day and who are at risk of developing non-steroidal anti-inflammatory drug associated gastric and/or duodenal ulcers. Horizon is seeking to license rights to DUEXIS in Europe to one or more commercial partners.
News For HZNP From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
July 2, 2015
07:03 EDTHZNPHorizon Pharma announces USPTO issuance of Notice of Allowance
Subscribe for More Information
June 26, 2015
07:28 EDTHZNPHorizon Pharma price target raised to $40 from $32 at UBS
Subscribe for More Information
June 23, 2015
07:36 EDTHZNPJMP Securities to hold a conference
Subscribe for More Information
07:12 EDTHZNPHorizon Pharma announces notice of allowance with claims covering Ravicti
Horizon Pharma announced that it has received from the United States Patent and Trademark Office a Notice of Allowance for U.S. patent application number 13/775,000, entitled "Methods of Therapeutic Monitoring of Nitrogen Scavenging Drugs" that covers Horizon's U.S. approved product Ravicti Oral Liquid.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use